Scarica l'app Stockscreener
22.22
8.07%
-1.95
Dopo l'orario di chiusura:
22.00
-0.22
-0.99%
Precedente Chiudi:
$24.17
Aprire:
$23.85
Volume 24 ore:
9.62M
Relative Volume:
2.28
Capitalizzazione di mercato:
$3.75B
Reddito:
$56.99M
Utile/perdita netta:
$-107.23M
Rapporto P/E:
-27.10
EPS:
-0.8199
Flusso di cassa netto:
$-142.55M
1 W Prestazione:
+1.46%
1M Prestazione:
-6.56%
6M Prestazione:
+3.06%
1 anno Prestazione:
+162.34%
Intervallo 1D:
$21.85
$24.11
Intervallo di 1 settimana:
$20.98
$24.47
Portata 52W:
$6.69
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
22.22 | 3.75B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-15 | Iniziato | JP Morgan | Overweight |
| 2026-06-26 | Aggiornamento | Jefferies | Hold → Buy |
| 2026-06-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-05-15 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2026-05-14 | Downgrade | Jefferies | Buy → Hold |
| 2026-04-02 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-23 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Form 4 Tango Therapeutics Inc For: 11 October By Investing.com - Investing.com UK
Form 4 Tango Therapeutics Inc For: 5 October By Investing.com - Investing.com Canada
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com
Tango therapeutics R&D president Adam Crystal sells $660k in shares. - Investing.com Canada
Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares - Stock Titan
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Tango Therapeutics principal accounting officer sells $198k in stock - Investing.com
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com Canada
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - finance.yahoo.com
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
H.C. Wainwright raises Tango Therapeutics price target to $68 - investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - stocktitan.net
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tango Therapeutics Inc Azioni (TNGX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Oct 01 '26 |
Sale |
24.47 |
27,000 |
660,796 |
115,743 |
| Jessica Newcomb | Officer |
Sep 22 '26 |
Proposed Sale |
22.33 |
15,231 |
340,108 |
0 |
| Newcomb Jessica | Principal Accounting Officer |
Sep 22 '26 |
Sale |
24.22 |
8,200 |
198,613 |
59,121 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Sep 01 '26 |
Sale |
22.37 |
27,000 |
603,909 |
115,743 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Sale |
27.24 |
27,000 |
735,517 |
115,743 |
| ADAM CRYSTAL | Officer |
Aug 03 '26 |
Proposed Sale |
27.18 |
81,000 |
2,201,580 |
0 |
| Crystal Adam | President, R&D |
Aug 03 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Sale |
29.59 |
27,000 |
798,908 |
115,743 |
| Crystal Adam | President, R&D |
Jul 01 '26 |
Option Exercise |
5.20 |
27,000 |
140,400 |
142,743 |
3.28%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):